Page 63 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 8 of 10 Review Article

44. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among 66. Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H. Predictors of
adult patients starting antiretroviral therapy in South Africa: A multicentre cohort loss to follow-up among children in the first and second years of antiretroviral
study. PLoS Med. 2012;9(9):e1001304. https://doi.org/10.1371/journal.pmed. treatment in Johannesburg, South Africa. Global Health Action. 2013;6:19248.
1001304 https://doi.org/10.3402/gha.v6i0.19248
45. Cornell M, Lessells R, Fox MP, et al. Mortality among adults transferred and lost to 67. Gsponer T, Weigel R, Davies MA, et al. Variability of growth in children starting
follow-up from antiretroviral therapy programmes in South Africa: A multicenter antiretroviral treatment in Southern Africa. Pediatrics. 2012;130(4):E966–E977.
cohort study. J Acquir Immune Defic Syndr. 2014;67(2):e67–e75. https://doi.org/ https://doi.org/10.1542/peds.2011-3020
10.1097/QAI.0000000000000269 68. Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children
46. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African on antiretroviral treatment receiving community-based adherence support:
adults starting antiretroviral treatment: Collaborative analysis of cohort studies. A multicentre cohort study from South Africa. AIDS Care. 2014;26(4):448–453.
PLoS Med. 2013;10(4):e1001418. https://doi.org/10.1371/journal.pmed.1001418 https://doi.org/10.1080/09540121.2013.855699
47. Fairall L, Bachmann MO, Lombard C, et al. Task shifting of antiretroviral treatment 69. Lilian RR, Kalk E, Technau K-G, Sherman GG. Birth diagnosis of HIV infection in
from doctors to primary-care nurses in South Africa [STRETCH]: A pragmatic, infants to reduce infant mortality and monitor for elimination of mother-to-child
parallel, cluster-randomised trial. Lancet (London, England). 2012;380:889–898. transmission. Pediatr Infect Dis J. 2013;32(10):1080–1085. https://doi.org/
https://doi.org/10.1016/S0140-6736(12)60730-2 10.1097/INF.0b013e318290622e
48. Fatti G, Meintjes G, Shea J, Eley B, Grimwood A. Improved survival and antiretroviral 70. Chhagan MK, Kauchali S, Van den Broeck J. Clinical and contextual determinants
treatment outcomes in adults receiving community-based adherence support: of anthropometric failure at baseline and longitudinal improvements after
5-year results from a multicentre cohort study in South Africa. J Acquir Immune starting antiretroviral treatment among South African children. Trop Med
Defic Syndr. 2012;61(4):e50–e58. https://doi.org/10.1097/QAI.0b013e31826a6aee Int Health. 2012;17(9):1092–1099. https://doi.org/10.1111/j.1365-3156.2012.
49. Johnston V, Fielding K, Charalambous S, et al. Second-line antiretroviral therapy 03026.x
in a workplace and community-based treatment programme in South Africa:
Determinants of virological outcome. PLoS One. 2012;7(5):e36997. https://doi. 71. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral
org/10.1371/journal.pone.0036997 therapy in children in South Africa. The IeDEA Southern Africa collaboration.
J Acquir Immune Defic Syndr. 2011;56(3):270–278. https://doi.org/10.1097/
50. Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S. A novel Markov QAI.0b013e3182060610
Model projecting costs and outcomes of providing antiretroviral therapy to public
patients in private practices versus public clinics in South Africa. PLoS One. 72. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to
2013;8(2):e53570. https://doi.org/10.1371/journal.pone.0053570 nevirapine to nevi rapine-based treatment after initial suppression with a
protease-inhibitor-based regimen: Long-term follow-up of a randomised, open-
51. Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient label trial. Lancet Infect Dis. 2012;12(7):521–530. https://doi.org/10.1016/S1473-
adherence groups as a model of care for stable patients on antiretroviral therapy 3099(12)70051-8
in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8(2):e56088. https://doi.
org/10.1371/journal.pone.0056088 73. Shiau S, Kuhn L, Strehlau R, et al. Sex differences in responses to antiretroviral
treatment in South African HIV-infected children on ritonavir-boosted lopinavir-
52. Mutevedzi PC, Lessells RJ, Newell M-L. Disengagement from care in a decentralised and nevirapine-based treatment. BMC Pediatr. 2014;14:39. https://doi.org/
primary health care antiretroviral treatment programme: Cohort study in rural 10.1186/1471-2431-14-39
South Africa. Trop Med Int Health. 2013;18(8):934–941. https://doi.org/10.1111/
tmi.12135 74. MacDonald P, Maskew M, Evans D, Levin L, Untiedt S, Sanne I. Paediatric human
immunodeficiency virus treatment outcomes from a resource-limited setting in
53. Schoffelen AF, Wensing AMJ, Tempelman HA, Geelen SPM, Hoepelman AIM, Barth South Africa: Highly active antiretroviral therapy alone is not enough. Vulnerable
RE. Sustained virological response on second-line antiretroviral therapy following Child Youth Stud. 2011;6(3):208–221. https://doi.org/10.1080/17450128.2011.
virological failure in HIV-infected patients in rural South Africa. PLoS One. 580020
2013;8(3):e58526. https://doi.org/10.1371/journal.pone.0058526
54. Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ. 75. Morsheimer MM, Dramowski A, Rabie H, Cotton MF. Paediatric ART outcomes in
a decentralised model of care in Cape Town, South Africa. S Afr J HIV Med.
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral 2014;15(4):148–153. https://doi.org/10.4102/sajhivmed.v15i4.332
therapy in a resource limited-setting: A cohort study. PLoS One. 2013;8(5):e64459.
https://doi.org/10.1371/journal.pone.0064459 76. Smith SJ, Nimmo C, Fredlund V, Moodley P. Early infant diagnosis of HIV and fast
55. Westreich D, Maskew M, Evans D, Firnhaber C, Majuba P, Sanne I. Incident initiation of anti-retroviral therapy in a rural African setting: How well are we
doing? Paediatr Int Child Health. 2014;34(3):203–207. https://doi.org/10.1179/2
pregnancy and time to death or AIDS among HIV-positive women receiving 046905514Y.0000000119
antiretroviral therapy. PLoS One. 2013;8(3):e58117. https://doi.org/10.1371/
journal.pone.0058117 77. Van Schalkwyk M, Andersson MI, Zeier MD, La Grange M, Taljaard JJ, Theron GB.
56. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, The impact of revised PMTCT guidelines: A view from a public sector ARV clinic in
Cape Town, South Africa. J Acquir Immune Defic Syndr. 2013;63(2):234–238.
nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25(13):1603– https://doi.org/10.1097/QAI.0b013e31828bb721
1609. https://doi.org/10.1097/QAD.0b013e32834957da
57. Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP. Gender 78. Clouse K, Pettifor A, Shearer K, et al. Loss to follow-up before and after delivery
differences in mortality and CD4 count response among virally suppressed among women testing HIV positive during pregnancy in Johannesburg,
HIV-positive patients. J Womens Health. 2013;22(2):113–120. https://doi.org/ South Africa. Trop Med Int Health. 2013;18(4):451–460. https://doi.org/10.1111/
10.1089/jwh.2012.3585 tmi. 12072
58. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, Wood R. Early outcomes and 79. Schwartz S, Clouse K, Yende N, et al. Acceptability and feasibility of a mobile
the virological effect of delayed treatment switching to second-line therapy in an phone-based case management intervention to retain mothers and infants
antiretroviral roll-out programme in South Africa. Antivir Ther. 2011;16(6):853–861. from an Option B+ program in postpartum HIV care. Matern Child Health
https://doi.org/10.3851/IMP1819 J. 2015;19(9):2029–2037. https://doi.org/10.1007/s10995-015-1715-0
59. Nglazi MD, Kaplan R, Orrell C, et al. Increasing transfers-out from an antiretroviral 80. Phillips T, Thebus E, Bekker L-G, McIntyre J, Abrams EJ, Myer L. Disengagement of
treatment service in South Africa: Patient characteristics and rates of virological HIV-positive pregnant and postpartum women from antiretroviral therapy
non-suppression. PLoS One. 2013;8(3):e57907. https://doi.org/10.1371/journal. services: A cohort study. J Int AIDS Soc. 2014;17:19242. https://doi.org/10.7448/
pone.0057907 IAS.17.1.19242
60. Loggerenberg F, Grant A, Naidoo K, et al. Individualised motivational counselling 81. Grimsrud A, Kaplan R, Bekker L-G, Myer L. Outcomes of a nurse-managed service
to enhance adherence to antiretroviral therapy is not superior to didactic for stable HIV-positive patients in a large South African public sector antiretroviral
counselling in South African patients: Findings of the CAPRISA 058 randomised therapy programme. Trop Med Int Health. 2014;19(9):1029–1039. https://doi.
controlled trial. AIDS Behav. 2015;19(1):145–156. https://doi.org/10.1007/ org/10.1111/tmi.12346
s10461-014-0763-6 82. Chi BH, Cantrell RA, Mwango A, et al. An empirical approach to defining loss
61. Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over to follow-up among patients enrolled in antiretroviral treatment programs. Am
time from cART start: Implications for care. J Acquir Immune Defic Syndr. J Epidemiol. 2010;171(8):924–931. https://doi.org/10.1093/aje/kwq008
2011;58(3):269–276. https://doi.org/10.1097/QAI.0b013e31823219d1 83. Grimsrud A, Ford N, Myer L. Defaulting from antiretroviral treatment programmes
62. Fatti G, Bock P, Eley B, Mothibi E, Grimwood A. Temporal trends in baseline in sub-Saharan Africa: A problem of definition. Trop Med Int Health. 2011;16(3):
characteristics and treatment outcomes of children starting antiretroviral 390–391.
treatment: An analysis in four provinces in South Africa, 2004-2009. J Acquir
Immune Defic Syndr. 2011;58(3):e60–e67. https://doi.org/10.1097/QAI.0b013e 84. Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access to engagement:
3182303c7e Measuring retention in outpatient HIV clinical care. AIDS Patient Care STDs.
2010;24(10):607–613. https://doi.org/10.1089/apc.2010.0086
63. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B. Community
adherence support improves programme retention in children on antiretroviral 85. Shepherd BE, Blevins M, Vaz LM, et al. Impact of definitions of loss to follow-up on
treatment: A multicentre cohort study in South Africa. J Int AIDS Soc. estimates of retention, disease progression, and mortality: Application to an HIV
2012;15(2):17381. https://doi.org/10.7448/IAS.15.2.17381 program in Mozambique. Am J Epidemiol. 2013;178(5):819–828. https://doi.org/
64. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy 10.1093/aje/kwt030
versus deferred therapy in South African infants infected with HIV: Results 86. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in
from the children with HIV early antiretroviral (CHER) randomised trial. sub-Saharan Africa: A systematic review. PLoS Med. 2007;4(10):e298. https://doi.
Lancet. 2013;382(9904):1555–1563. https://doi.org/10.1016/S0140-6736(13) org/10.1371/journal.pmed.0040298
61409-9 87. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three
65. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses years on treatment in sub-Saharan Africa, 2007-2009: Systematic review. Trop
among children attending a large public clinic in Soweto, South Africa. Pediatr Med Int Health. 2010;15 (Suppl 1):1–15. https://doi.org/10.1111/j.1365-3156.
Infect Dis J. 2011;30(11):974–979. https://doi.org/10.1097/INF.0b013e31822539f6 2010.02508.x
http://www.sajhivmed.org.za 56 Open Access